AKT1 and neoplasm: Although PI3K and AKT inhibitors efficiently target disseminating CD44v6+ CR-CSCs, their anti-tumor activity was found to be dramatically reduced in pre-clinical mouse models, where the presence of a protective TME counteracted drug efficacy [11,17].